Browsing Faculty of Health Sciences by Subject "Caffeine"
Now showing items 1-10 of 15
-
8-(3-phenylpropyl)-1,3,7-triethylxanthine is a synthetic caffeine substitute with stronger metabolic modulator activity
(Elsevier, 2018)Caffeine is one of the most worldwide consumed methylxanthines. It is well-known for its thermogenic and cell metabolism modulating effects. Based on methylxanthines' chemical structure, 8-(3-phenylpropyl)-1,3,7-triethylxanthine ... -
8-Aryl- and alkyloxycaffeine analogues as inhibitors of monoamine oxidase
(Elsevier, 2011)Recently it was reported that a series of 8-benzyloxycaffeine analogues are potent reversible inhibitors of human monoamine oxidase (MAO) A and B. In an attempt to discover additional C8 oxy substituents of caffeine that ... -
Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson’s disease
(Bentham Science, 2015)The current pharmacological therapies for the treatment of Parkinson’s disease are mostly inadequate and recent, improved therapeutic agents are required. Two important molecular targets for the design of anti-parkinsonian ... -
Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine A1 and A2A receptor antagonists
(Elsevier, 2016)Based on a previous report that a series of 8-(phenoxymethyl)-xanthines may be promising leads for the design of A1 adenosine receptor antagonists, selected novel and known 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine ... -
Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E)-8-(4phenylbytadien-1-yl) caffeine analogues
(Elsevier, 2008)The adenosine A2A receptor has emerged as an attractive target for the treatment of Parkinson’s disease (PD). Evidence suggests that antagonists of the A2A receptor (A2A antagonists) may be neuroprotective and may help to ... -
Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease
(Springer, 2009)Inadequacies of the current pharmacotherapies to treat Parkinson’s disease (PD) have prompted efforts to identify novel drug targets. The adenosine A2A receptor is one such target. Antagonists of this receptor (A2A ... -
The inhibition of monoamine oxidase by 8-(2-phenoxyethoxy) caffeine analogues
(Thieme, 2012)Previous studies have documented that substituted 8-oxycaffeines act as inhibitors of human monoamine oxidase (MAO) B. A particularly potent inhibitor among the reported compounds was 8-(2-phenoxyethoxy)caffeine with an ... -
Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues
(Elsevier, 2012)In a previous study we have investigated the monoamine oxidase (MAO) inhibitory properties of a series of 8-sulfanylcaffeine analogues. Among the compounds studied, 8-[(phenylethyl)sulfanyl]caffeine (IC50 = 0.223 lM) was ... -
Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues
(Elsevier, 2010)Based on recent reports that several (E)-8-styrylcaffeinyl analogues are potent reversible inhibitors of monoamine oxidase B (MAO-B), a series of 8-benzyloxycaffeinyl analogues were synthesized and evaluated as inhibitors ... -
Inhibition of monoamine oxidase by 8-phenoxymethylcaffeine derivatives
(Elsevier, 2012)A recent study has reported that a series of 8-benzyloxycaffeines are potent and reversible inhibitors of both human monoamine oxidase (MAO) isoforms, MAO-A and -B. In an attempt to discover additional caffeine derivatives ...